1.8 billion angina drugs! The Beijing pharmaceutical company will take it.

Pharmaceutical Network September 1st, August 26th, Beijing Baimett Bio according to the imitation of 4 categories of reported hydrochloric acid quercetaluene slow release tablets (receiving number CYHS1800211) registration status changed to "in approval", is expected to be approved in recent days and treated as a review.
2019, China's public medical institutions terminal Qumeitazine sales of more than 1.8 billion yuan, Schweija accounted for 65.26 percent of the market share.
quretatin is an anti-angina drug that prevents the decline of ATP levels in cells by protecting the energy metabolism of cells in the absence of oxygen or ischemia, thus ensuring the normal function of the ion pump and the normal operation of the sodium-potassium flow through the membrane, and maintaining the stability of the intracellular environment.
was developed by Schweija, the earliest available dosage form for ordinary tablets, and then in 2001 listed hydrochloric acid quentinate slow release tablets.
intranet data show that in 2019, China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal Qumeitazine sales of more than 1.8 billion yuan.
, Schweinstinger has a market share of 65.26 percent, Ruiyang Pharmaceuticals 13.15 percent and Beijing Fuyuan Pharmaceuticals 8.68 percent.
the current domestic market of Qumeitazine products have capsules, tablets and slow release tablets, capsules have not been evaluated by enterprises.
Hydrochloric acid quercetazine slow release tablets for the second batch of collection varieties, the winning enterprises are Hengrui Pharmaceuticals, Qilu Pharmaceuticals, Hanyu Pharmaceuticals;
Hydrochloric acid quercetamin slow release film evaluation enterprise Mi net consistency evaluation database shows that hydrochloric acid quretamin slow release tablets over-evaluation enterprises have 5, respectively, Hengrui Pharmaceuticals, Qilu Pharmaceuticals, Beijing Fuyuan Pharmaceuticals / Hanyu Pharmaceuticals, Zhengzhou Taifeng Pharmaceuticals.
The registration status of Beijing Baimeit Bio's hydrochloric acid quercetazine slow release film has been changed to "in the approval", if successfully approved will be treated as a review, become the sixth evaluation enterprise of the species.
source: MiNet Database, NMPA.